Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Corcept Therapeutics Inc

CORT ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Large Cap Analyst: BUY

Last Close

$114.47

▲ +3.58%

Market Cap $12.37B · Vol 264.39K

Key Metrics

P/E Ratio

268.68

FWD: 34.89

Market Cap

$12.37B

Large Cap

Div Yield

N/A

EPS Growth

+96.04%

YoY

RSI (14)

70.69

Momentum

Beta

0.44

vs Market

52W High

$122.12

6.26% below

52W Low

$28.68

299.13% above

Volume

264.39K

Avg 482.46K

P/B

5.69

Price-to-book

ROE

14.79%

Return on equity

Free Float

88.25%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Corcept Therapeutics Inc (CORT) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CORT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+3.34%

+26.53%

+96.35%

+186.39%

YTD

+228.94%

+58.99%

+269.74%

+453.53%

Financials & Valuation

TTM · Annual

Total Revenue	$761.41M
Net Income	$99.65M
Revenue Growth (YoY)	+31.74%
Gross Margin	98.30%
Operating Margin	5.88%
Net Profit Margin	13.09%
ROE	14.79%
ROA · ROIC	7.93% · 15.01%

P/E Ratio	268.68
Forward P/E (FY1)	34.89
PEG Ratio	-1.26
P/S	5.48
P/B	5.69
P/FCF	29.45
EPS Growth	+96.04%
Outstanding Shares	108.10M

Technical Indicators

50-Day SMA	$92.88
200-Day SMA	$63.62
RSI (14)	70.69
Beta	0.44
52-Week High	$122.12
52-Week Low	$28.68

Volume Today	264.39K
Avg Daily Volume (30D)	482.46K
Relative Volume	0.55x
Volatility (10D)	35.93
Volatility (30D)	83.30
Free Float	88.25%

Analyst Consensus

BUY

Current Price $114.47

Mean Target $119.81

52W Low$28.68 52W High$122.12

Current

Target

$28.68 $122.12

Current Analyst target

+4.66% upside potential · 6 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S8QGV1

ISINUS2183521028

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. It is also conducting advanced clinical trials in patients with solid tumors, Amyotrophic Lateral Sclerosis (ALS) and liver disease. It operates through the discovery, development and commercialization of the pharmaceutical products segment. It sells Korlym and a generic version of Korlym in the United States using sales representatives to call on physicians caring for patients with hypercortisolism (Cushing’s syndrome). The Company's portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. It sells and distributes Lifyorli in the United States. It is developing its proprietary, selective cortisol modulator, relacorilant, as a treatment for patients with hypercortisolism.